Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has appointed Patrick Connor as its new vice president of research, Michael LaBarre as vice president of product development and James Cartoni as vice president of legal affairs.
Subscribe to our email newsletter
Dr Connor joins Halozyme from Ardea Biosciences where he was senior vice president and chief scientific officer. His responsibilities will include leadership of Halozyme’s multiple biology and chemistry research programs.
Dr LaBarre has previously served as vice president of product development at Paramount BioSciences. He will oversee all of Halozyme’s product development efforts, bringing strong experience in chemistry, manufacturing and controls based on his extensive experience in the biotechnology industry for both biologics and small molecules.
Prior to joining Halozyme, Mr Cartoni was a partner at DLA Piper, a law firm. He will oversee various legal matters, including the negotiation and completion of agreements, corporate governance matters, securities compliance, and the coordination and management of outside legal counsel.
Jonathan Lim, president and CEO of Halozyme Therapeutics, said: “We are delighted that seasoned executives such as Patrick, Michael, and Jim have joined the team. Their broad collective experience in drug development, formulation, analytical methodology, manufacturing, and the legal aspects of biotechnology brings further breadth and depth to our leadership team.”